Next 10 |
home / stock / xvipf / xvipf news
GOTHENBURG, SWEDEN / ACCESSWIRE / April 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) First quarter 2024 (Jan 1 - Mar 31) • Net sales amounted to SEK 186.0 million (140.6), corresponding to an increase of 32 percent in SEK and equivalent increase, 32 percent, adjusted ...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 11, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech Republic, the results from XVIVO's clinical trial, NIHP2019, in heart transplantation were pres...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 4, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today XVIVO Perfusion AB (publ) publish the Annual Report for 2023. The Annual Report is attached to this press release in pdf format and in ESEF format (European Single Electronic Format) and is...
GOTHENBURG, SWEDEN / ACCESSWIRE / March 21, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) (publ) (the "Company"), reg. no. 556561-0424, with its registered office in Mölndal, gives notice of the Annual General Meeting to be held on Thursday 25 April 2024 at 2:00 PM, at The Swedis...
GOTHENBURG, SE / ACCESSWIRE / February 29, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) The Lancet reports[1] that for the first time in medical history, transportation of a donor heart has been performed across the Atlantic Ocean. After preservation outside the body for more than 12...
2024-02-07 10:28:09 ET Summary TransMedics has a dominant market position in the organ transplant market due to its revolutionary Organ Care System product, which helps organs survive longer, enabling significantly greater reach. At 15x TTM P/S and 9x NTM P/S, TransMedics stock is...
GOTHENBURG, SWEDEN / ACCESSWIRE / January 25, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Fourth quarter 2023 (October 1 - December 31) • Net sales amounted to SEK 155.7 million (131.5), corresponding to an increase of 18 percent in SEK and 16 percent in local currencies....
GOTHENBURG, SE / ACCESSWIRE / January 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) In a recently published [1] clinical trial conducted by the UMCG in Groningen, the Netherlands, XVIVO's Liver Assist has demonstrated its potential to reshape liver transplant logistics. The trial...
GOTHENBURG, SE / ACCESSWIRE / January 12, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Invitation to attend XVIVO's conference call regarding the presentation of the Report on Operations 2023. The presentation will be held in English. Time: Thursday, January 25 at 2.00 pm. CET If...
GOTHENBURG, SWEDEN / ACCESSWIRE / December 22, 2023 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) In 2014, XVIVO introduced an innovative liver technology to the Italian market, designed for oxygenated perfusion prior to transplantation. Today, we are proud to announce that we have reached...
News, Short Squeeze, Breakout and More Instantly...
Xvivo Perfusion Ab Ord Company Name:
XVIPF Stock Symbol:
OTCMKTS Market:
GOTHENBURG, SWEDEN / ACCESSWIRE / April 24, 2024 / XVIVO Perfusion AB (STO:XVIVO) (LSE:0RKL)(FRA:3XV) First quarter 2024 (Jan 1 - Mar 31) • Net sales amounted to SEK 186.0 million (140.6), corresponding to an increase of 32 percent in SEK and equivalent increase, 32 percent, adjusted ...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 11, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today, at the 2024 International Society of Heart and Lung Transplantation meeting in Prague, Czech Republic, the results from XVIVO's clinical trial, NIHP2019, in heart transplantation were pres...
GOTHENBURG, SWEDEN / ACCESSWIRE / April 4, 2024 / XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) Today XVIVO Perfusion AB (publ) publish the Annual Report for 2023. The Annual Report is attached to this press release in pdf format and in ESEF format (European Single Electronic Format) and is...